You just read:

Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis

News provided by

Sanofi

Mar 28, 2017, 11:40 ET